Brevinin-1BYa: a naturally occurring peptide from frog skin with broad-spectrum antibacterial and antifungal properties

International Journal of Antimicrobial Agents

Volumn 27, Issue 6, 2006, Pages 525-529

  Pál, Tibor ^a   Abraham, Bency ^a   Sonnevend, Ágnes ^a   Jumaa, Pauline ^a   Conlon, J Michael ^a  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

Author keywords

Antibacterial and antifungal peptide; Brevinin 1; Frog skin

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; BREVININ 1BYA; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CANDIDA ALBICANS; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CONTROLLED STUDY; ERYTHROCYTE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEMOLYSIS; HUMAN; HUMAN CELL; LD 50; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; AMPHIBIAN PROTEINS; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA;

EID: 33646756145     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2006.01.010     Document Type: Article

References (33)

1. Norrby S.R., Nord C.E., and Finch R. Lack of development of new antimicrobial drugs: a potential serious threat to public health. Lancet Infect Dis 5 (2005) 115-119
2. Hoffmann J.A., Kafatos F.C., Janeway C.A., and Ezekowitz R.A. Phylogenetic perspectives in innate immunity. Science 284 (1999) 1313-1318
3. Hancock R.E. Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect Dis 1 (2001) 156-164
4. Hancock R.E., and Patrzykat A. Clinical development of cationic antimicrobial peptides: from natural to novel antibiotics. Curr Drug Targets Infect Disord 2 (2002) 79-83
5. Conlon J.M. The therapeutic potential of antimicrobial peptides from frog skin. Rev Med Microbiol 15 (2004) 17-25
6. Yeaman M.R., and Yount N.Y. Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev 55 (2003) 27-55
7. Zasloff M. Antimicrobial peptides in health and disease. N Engl J Med 347 (2002) 1199-1200
8. Ge Y., MacDonald D., Henry M.M., et al. In vitro susceptibility to pexiganan of bacteria isolated from infected diabetic foot ulcers. Diagn Microbiol Infect Dis 35 (1999) 45-53
9. Kyle A.A., and Dahl M.V. Topical therapy for fungal infections. Am J Clin Dermatol 4 (2004) 443-451
10. Conlon J.M., Kolodziejek J., and Nowotny N. Antimicrobial peptides from ranid frogs: taxonomic and phylogenetic markers and a potential source of new therapeutic agents. Biochim Biophys Acta 1696 (2004) 1-14
11. Giangaspero A., Sandri L., and Tossi A. Amphipathic α-helical peptides. A systematic study of the effects of structural and physical properties on biological activity. Eur J Biochem 268 (2001) 5589-5600
12. Conlon J.M., Sonnevend A., Patel M., et al. Isolation of peptides of the brevinin-1 family with potent candidacidal activity from the skin secretions of the frog Rana boylii. J Pept Res 62 (2003) 207-213
13. Pál T., Sonnevend A., Galadari S., and Conlon J.M. Design of potent, non-toxic antimicrobial agents based upon the structure of the frog skin peptide, pseudin-2. Regul Pept 129 (2005) 85-91
14. Louie L., Goodfellow J., Mathieu P., Glatt A., Louie M., and Simor A.E. Rapid detection of methicillin-resistant staphylococci from blood culture bottles by using a multiplex PCR assay. J Clin Microbiol 40 (2002) 2786-2790
15. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard M7-A4 (1997), NCCLS, Wayne, PA
16. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeast. Approved Standard M27-A2 (2002), NCCLS, Wayne, PA
17. Morikawa N., Hagiwara K., and Nakajima T. Brevinin-1 and -2, unique antimicrobial peptides from the skin of the frog, Rana brevipoda porsa. Biochem Biophys Res Commun 189 (1992) 184-190
18. Kwon M.Y., Hong S.Y., and Lee K.H. Structure-activity analysis of brevinin 1E amide, an antimicrobial peptide from Rana esculenta. Biochim Biophys Acta 1387 (1998) 239-248
19. Park S.H., Kim H.E., Kim C.M., Yun H.J., Choi E.C., and Lee B.J. Role of proline, cysteine and a disulphide bridge in the structure and activity of the anti-microbial peptide gaegurin 5. Biochem J 368 (2002) 171-182
20. Won H.S., Jung S.J., Kim H.E., Seo M.D., and Lee B.J. Systematic peptide engineering and structural characterization to search for the shortest antimicrobial peptide analogue of gaegurin 5. J Biol Chem 279 (2004) 14784-14791
21. Conlon J.M., Sonnevend A., Jouenne T., et al. A family of acyclic brevinin-1 peptides from the skin of the Ryukyu brown frog Rana okinavana. Peptides 26 (2005) 185-190
22. Senior B.W. Investigation of the types and characteristics of the proteolytic enzymes formed by diverse strains of Proteus species. J Med Microbiol 48 (1999) 623-628
23. Jevons M.P. 'Celbenin' resistant staphylococci. Br Med J 1 (1961) 124-125
24. Diekema D.J., Pfaller M.A., Schmitz F.J., et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 32 Suppl 2 (2001) S114-S132
25. Zetola N., Francis J.S., Nuermberger E.L., and Bishai W.R. Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat. Lancet Infect Dis 5 (2005) 275-286
26. Barrett J.F. MRSA: status and prospects for therapy? An evaluation of key papers on the topic of MRSA and antibiotic resistance. Expert Opin Ther Targets 8 (2004) 515-519
27. Prasad R., and Kapoor K. Multidrug resistance in yeast Candida. Int Rev Cytol 242 (2005) 215-248
28. Richardson M.D. Changing patterns and trends in systemic fungal infections. J Antimicrob Chemother 56 Suppl 1 (2005) i5-i11
29. Pierce G.E. Pseudomonas aeruginosa, Candida albicans, and device-related nosocomial infections: implications, trends, and potential approaches for control. J Ind Microbiol Biotechnol 32 (2005) 309-318
30. Dennison S.R., Wallace J., Harris F., and Phoenix D.A. Amphiphilic α-helical antimicrobial peptides and their structure/function relationships. Protein Pept Lett 12 (2005) 31-39
31. Wieprecht T., Dathe M., Krause E., et al. Modulation of membrane activity of amphipathic, antibacterial peptides by slight modifications of the hydrophobic moment. FEBS Lett 417 (1997) 135-140
32. Dathe M., Wieprecht T., Nikolenko H., et al. Hydrophobicity, hydrophobic moment and angle subtended by charged residues modulate antibacterial and haemolytic activity of amphipathic helical peptides. FEBS Lett 403 (1997) 208-212
33. Conlon J.M., Abraham B., Galadari S., Knoop F.C., Sonnevend A., and Pál T. Antimicrobial and cytolytic properties of the frog skin peptide, kassinatuerin-1 and its l- and d-lysine-substituted derivatives. Peptides 26 (2005) 2104-2110